Related Experiment Videos
Hemobiological properties of gliclazide
Journal of Diabetes and Its Complications
|October 1, 1994
Summary
Gliclazide, a sulfonylurea, improves blood clotting and fibrinolysis in type II diabetes mellitus (NIDDM) patients. It also exhibits antioxidant properties, potentially reducing oxidative stress and platelet reactivity.
Area of Science:
- Endocrinology
- Pharmacology
- Hematology
Background:
- Non-insulin-dependent diabetes mellitus (NIDDM) increases risks of vascular complications.
- Gliclazide is a widely used second-generation sulfonylurea for type II diabetes.
- NIDDM is linked to hemobiological abnormalities, including platelet dysfunction and impaired fibrinolysis.
Purpose of the Study:
- To investigate the hemobiological effects of gliclazide in NIDDM patients.
- To evaluate gliclazide's impact on platelet function, fibrinolysis, and oxidative stress.
Main Methods:
- Review of numerous studies on gliclazide's effects.
- Analysis of platelet function markers (beta thromboglobulin, thromboxane B2).
- Assessment of fibrinolysis (plasminogen, tissue plasminogen activator, pre-kallikrein) and prostacyclin synthesis.
- In vitro and in vivo evaluation of free-radical-scavenging activity.
Main Results:
- Gliclazide reduces platelet hyperadhesion and hyperaggregability.
- It normalizes low plasminogen activity and enhances fibrinolytic potential.
- Gliclazide stimulates endothelial prostacyclin synthesis and improves the thromboxane/prostacyclin balance.
- The drug demonstrates potent free-radical-scavenging activity in vitro and in vivo.
Conclusions:
- Gliclazide offers significant benefits beyond glucose lowering in NIDDM.
- Its effects on hemobiological abnormalities may mitigate vascular complications.
- Gliclazide's antioxidant properties suggest a link between oxidative stress and platelet reactivity in diabetes.